Clinical trials: Desmoid-Type Fibromatosis
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Neoplasm, Desmoid Tumor
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.
- Trial name
- NCT02955446
- Testing
- PF-03084014
- Where
- United States
- Sponsor
- University of Colorado, Denver
Desmoid Tumor
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid-type fibromatosis (or desmoid tumor) represents an intermediate grade neoplasm with a striking predilection for locally invasive growth and recurrence following resection. It occurs in children as well as young adults.
- Trial name
- NCT01265030
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- MaineHealth
Desmoid
Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation
Desmoid tumors (DT) are uncommon tumors that arise from musculoaponeurotic structures. Despite benign, they can cause pain and disability due to their tendency to be locally aggressive.
- Trial name
- Cryomics (NCT06224283)
- Testing
- Cryoablation
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Ortopedico Rizzoli
Desmoid Tumors, Fibromatosis
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
The purpose of this study is to examine the response rate of desmoid tumors to hydroxyurea. The investigators hypothesize that hydroxyurea will be a safe, non-toxic alternative to aggressive surgery or chemotherapy for this…
- Trial name
- NCT00978146
- Testing
- Hydroxyurea
- Sponsor
- Children's Hospital of Philadelphia
Desmoid-type Fibromatosis
Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients
This is a prospective, multicenter observational study under the umbrella of the ISG (Italian Sarcoma Group) evaluating local progression-free survival at 3 years of patients affected by extra-abdominal primary fibromatosis…
- Trial name
- NCT02547831
- Testing
- Observational approach
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Deep Fibromatosis/Desmoid Tumor, Familial Adenomatous Polyposis
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
This pilot clinical trial studies fluorine (F)-18 16 alpha-fluoroestradiol (18F-FES) positron emission tomography (PET)/computed tomography (CT) in imaging patients with desmoid tumors.
- Trial name
- NCT02374931
- Testing
- F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Desmoid Type-fibromatosis
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
This is a prospective study evaluating the activity and the safety of toremifene in patients with primary or recurrent sporadic DTs.
- Trial name
- NCT02353429
- Testing
- Toremifene
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After
Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local…
- Conditions
- The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After, Surgical Resection
- Trial name
- NCT01898416
- Testing
- 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
- Where
- 2 sites in Israel
- Volunteers
- 140 people
- Sponsor
- michal roll
Desmoid, Desmoid Tumor
A Study of AL102 in Patients With Progressing Desmoid Tumors
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
- Trial name
- RINGSIDE (NCT04871282)
- Testing
- AL102
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 198 people
- Sponsor
- Immunome, Inc.
Desmoid Tumor
Toremifene in Treating Patients With Desmoid Tumors
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.
- Trial name
- NCT00002595
- Testing
- toremifene, conventional surgery
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Advocate Lutheran General Hospital
Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
The purpose of this study is to determine if Magnetic Resonance guided High Intensity Focused Ultrasound ablative therapy is safe and feasible for children, adolescents, and young adults with refractory or relapsed solid tumors.
- Conditions
- Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT02076906
- Testing
- Magnetic Resonance High Intensity Focused Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- AeRang Kim
Desmoid, Desmoid; Abdominal
Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History.
Desmoid tumors (DT) are rare disease of intermediate malignancy with variable and often unpredictable clinical course. There is a growing interest in defining potential risk of recurrence or progression during or after pregnancy…
- Conditions
- Desmoid, Desmoid; Abdominal, Pregnancy Loss, Pregnancy Complications
- Trial name
- NCT05284305
- Testing
- Pregnancy
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 400 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid Tumor, Aggressive Fibromatoses
Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors
This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom…
- Trial name
- NCT07755176
- Testing
- Desmoid tumor ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret
Fibromatosis
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors
There is research supporting treatment of superficial fibromatoses (palmar fibromatosis and keloids) with triamcinolone acetonide injections. These lesions are histologically similar to deep fibromatoses (desmoid tumors).
- Trial name
- NCT03627741
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
- Trial name
- NCT07176689
- Testing
- Nirogacestat
- Where
- 23 sites in Belgium, Germany and 4 more
- Volunteers
- 50 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany